Institutional investors hold a majority ownership of ALXN through the 98.81% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
T. ROWE PRICE ASSOCIATES, INC. Bought 138.0 Thousand shares of Alexion Pharmaceuticals I...